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a-melanocyte stimulating hormone (a-MSH), a peptide that occurs within the brain, the
circulation, and other body sites, is a potent antipyretic agent when given centrally or peripher-
ally. The peptide likewise inhibits inflammation and aspects of the acute-phase response. The
combined evidence suggeststhata-MSH molecules act as natural modulators ofhostreactions by
antagonizing thecentral and peripheral actions ofcytokines.
It is clear that cytokines released in response to disease, tissue injury, or inflamma-
tion are very powerful inducers of cellular and systemic reactions of the host. These
cytokines, including interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor
(TNF), and soon, can act separately, although in nature they are likely toact together,
to induce inflammation, the acute-phase response, and changes in activity of the
immune system. No diseases have yet been identified that are associated specifically
with surplus cytokine activity, although there is considerable speculation about cyto-
kines in many disorders, including arthritis. The speculation stems from the powerful
influence of the cytokines on physiological processes, and this same influence suggests
that there must be endogenous modulation of their effects to prevent severe damage
and to ensure survival of the host. Neuropeptides, such as a-melanocyte stimulating
hormone (a-MSH) that exist within the central nervous system (CNS) [1,2] and in
other parts of the body and that also increase in the circulation after challenge with
endogenous pyrogen or bacterial endotoxin [3], may modulate the effect of cytokines
either directly or indirectly.
THE a-MSH MOLECULE, FUNCTION AND LOCALIZATION
Thea-MSH molecule is ancient and has been found within the CNSofinvertebrates
and lower vertebrates, such as fish [4], as well as in higher organisms [5]. Detailed
analysis of its structure, processing, chemistry, distribution, and the like can be found
in a recent extensive review on the peptide by A. Eberle [5]. a-MSH (1-13) has the
same amino acid sequence as ACTH (1-13) (Fig. 1), and in certain tissues (e.g.,
intermediate lobe of the pituitary, arcuate nucleus, nucleus of the solitary tract) it is
derived from ACTH, which in turn is derived from its precursor POMC. In the dorsal
hypothalamus, the a-MSH (1-13) peptide develops de novo without processing of
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FIG. 1. Amino acid sequenceofa-MSH.
ACTH or other POMC molecules [6]. The molecule is named for its capacity to
darken the skinofamphibians (see [5]), but it has little pigmentaryactivityin man [7].
The effect ofa-MSH on skin chromatophores, which are ontogenetically derived from
the neural crest, is to alter color. Melanocytes, melanophores of birds and mammals,
primarily synthesize brown/black melanin and may be influenced by a-MSH, but the
physiological role ofthe peptide in mammalian pigmentation is not clear.
In higher organisms no physiological role for a-MSH has been clearly established.
There is, however, considerable evidence that the peptide can influence learning and
memory [5,8]. This influence is more likely the result of actions on attention and
arousal rather than on learning and memory processes per se. Evidence is developing
that a-MSH exerts trophic actions within the peripheral and central nervous systems.
a-MSH appears to stimulate neurite outgrowth [9], the initial regeneration or sprout-
ing response to peripheral nerve injury [10,11], and to facilitate recovery from CNS
lesions [12,13]. Because such injuries induce host responses such as inflammation, it is
important to learn if the trophic effects of a-MSH in nervous tissue are related to
antagonism ofcytokines and cytotoxins.
a-MSH is found in high concentrations within the pituitary (e.g., [2]), and it has
been identified as an important component of the neuroendocrine system for many
years. The peptide also exists in mammalian skin [14], and a-MSH receptors are
widespread in the body [15]. The peptide occurs naturally in the circulation, and oneof
the early links between a-MSH and immune responses was thediscovery ofthepeptide
in lymphocytes [16].
ANTIPYRETIC ACTIVITY OF a-MSH
Fever is an aspect ofhost response to disease and injury. It is an elevation in the level
around which body temperature is regulated and is believed to result from the action of
cytokines on neurons, particularly thermosensitive neurons that resideprimarilywithin
the preoptic/anterior hypothalamic region of the brain, the site of primary tempera-
ture control. Indeed, although hyperthermia, a non-regulated rise in temperature, can
be induced via peripheral or central actions ofcertain agents, fever can occur only via
an action ofpyrogens on CNS temperature controls. It is not certain whether cytokines
induce, or always induce, release of prostaglandins of the E series as intermediates in
their influence on thermoregulatory neurons. The mechanisms ofantipyreticactivityof
common antipyreticdrugs is also uncertain and may involvecompetitiveantagonism of
cytokines, inhibition ofsynthesis ofprostaglandin mediators, and so on [17].
a-MSH, first reported to reduce fever in 1981 ([18]; see reviews [19-24]), has
subsequently been found, when given by several routes (Table 1), to inhibit fever
caused in rabbits by endogenous pyrogen. The consistency of the antipyretic response
to the peptide when it is given by multiple routes is remarkable, and it suggests a
uniform activity ofthe molecule to limit host reaction. The potency ofthe peptide also
suggests a role forendogenous a-MSH in fevercontrol: on a molarbasis, it is morethan
25,000 times more potent than acetaminophen in reducing fever when given intracere-
broventricularly (icv) andapproximately 20,000times morepotentwhengiven intrave-
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TABLE 1.
Antipyretic Effect ofa-MSH Given by Various Routes to Febrile Rabbits
Route Dose Reference
icv ng range e.g., Glyn and Lipton [18]
iv < 1 Mg/kg e.g., Glyn and Lipton [18]
Intragastric < 1 mg/kg Murphy and Lipton [25]
Intra-septal Mg Glyn-Ballinger et al. [26]
Intra-PO/AH 350 ,g Feng et al. [27]
nously (iv) [28]. The action ofthe peptide is much like that ofantipyretic drugs in that,
in antipyretic doses, it reduces fever without altering normal body temperature, even in
the cold [29]. The antipyretic influence ofa-MSH is not peculiar to the rabbit. It has
also been observed in mice [30-32], guinea pigs [33], and squirrel monkeys [34].
Although the bulk of research has been performed with endogenous pyrogens, crude
products ofincubation ofleukocytes with endotoxin that undoubtedly contain interleu-
kins, TNF, and other cytokines, a-MSH is also effective against fever caused by
lipopolysaccharide [20] and by IL-1 and TNF [30-32,35]. Our recent research
indicates that it also reduces fever caused by IL-6 [Martin LW, Lipton JM: unpub-
lished observation]. In one study [35] a-MSH also antagonized the effect of IL-1: on
measures of sleep. It is noted below that, although a-MSH antagonizes the actions of
cytokines, it does not inhibit hyperthermia-caused prostaglandin E, a presumed
mediator offever, or that caused by prostaglandin precursor arachidonic acid.
Questions remain about the relative importance ofspecific neuroanatomical sites to
a-MSH modulation of fever control. Although it is hazardous to speculate from
comparisons of dose effectiveness when the peptide is injected centrally, the results in
Table 1 do suggest some possibilities. It is clear that large amounts of a-MSH are
required to reduce fever when the peptide is injected into the PO/AH region, which
suggests that this location may not be the primary site of its antipyretic action.
Depending on the specific site, nanogram to ,ug doses are required to reduce fever when
a-MSH is injected into the septal region, which suggests that the septum is more
important, or at least more sensitive, than the PO/AH region; however, doses of
at-MSH in the nanogram range have marked effects on fever when injected into the
cerebral ventricles. This latter observation suggests, but does not prove, that the
a-MSH receptors that are important to the antipyretic activity of the peptide are
widely distributed within the CNS. Indeed, doses less than 1 ,g/kg given iv cause
marked reductions in fever. It is likely that little ofthis peptide reaches central sites of
action. These observations must be treated with caution, for there is much that is
unknown about processing and action ofca-MSH within localized CNS sites. It may be
that very small amounts ofa-MSH within specific sites are important to fever control.
Similar observations ofdifferences in potency ofpeptides injected into CNS tissue and
into the cerebral ventricles have been common in neuroendocrine studies. Such
observations, alone, can only provide hypotheses about the relative importance ofCNS
sites ofaction.
PHYSIOLOGICAL ROLE OF a-MSH IN FEVER CONTROL
The antipyretic potency ofa-MSH and its effectiveness in a number of homeother-
mic species raised the question of a role of the endogenous peptide in regulation of
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fever. Three types of evidence were developed that are consistent with the idea that
a-MSH is important to a naturally occurring fever modulation system within the CNS.
First, it was noted that the concentration of a-MSH within the septal region, but not
elsewhere, rose during fever [36,37] but not during hyperthermia induced by exposure
to a hot environment [37]. In related experiments (Table 1), microinjection ofa-MSH
into this region reduced fever [26]. In push-pull studies, the concentration of a-MSH
was increased in a pulsatile fashion during fever, but not during normothermia [38].
The timing of onset of the pulses suggested a direct action of cytokines on induction of
the pulses. Third, in passive immunoneutralization experiments, antiserum specific for
a-MSH enhanced, especially in duration, fever after intravenous (iv) injection of
endogenous pyrogen [39]. Thus, binding and inactivation of endogenous a-MSH has a
marked effect on fever. The combined results of these experiments, against a back-
ground of research on a-MSH administration, suggested that the peptide is a vital
feature of an endogenous CNS mechanism that modulates the pyrogenic effect of
cytokines and prevents dangerous rises in core temperature.
THE ANTIPYRETIC MESSAGE SEQUENCE OF a-MSH
In initial studies of the effects of neuropeptides on fever, ACTH (1-24) was likewise
found to have antipyretic activity [18]; however, because a-MSH was effective, the
antipyretic property of the larger ACTH molecule was not studied in detail. It was
noted that the antipyretic effect of centrally and peripherally administered ACTH
(1-24) does not depend upon release ofcorticosteroids from the adrenal gland [40], but
repeated administration of ACTH can cause Cushing's syndrome, which would limit
the usefulness of the molecule for treatment of fever.
In early tests, the focus was upon N-terminal and intermediate fragments of
a-MSH, and a-MSH (1-3), a-MSH (1-4), a-MSH (4-8), a-MSH (4-9), and so on,
were found to be ineffective [unpublished observations]. a-MSH (1-10) was likewise
inactive, as were larger fragments ofACTH such as CLIP (18-39) [19]. The combined
results suggest that the COOH-terminal tripeptide, a-MSH (11-13), is the antipyretic
message sequence. This fragment was discovered to have antipyretic activity when
given centrally or iv, although the doses required were greater than for a-MSH (1-13)
[41]. More recently [42], a-MSH (11-13) given icv reduced fever in a dose-related
fashion. a-MSH (10-13) was also antipyretic but less potent than a-MSH (11-13);
a-MSH (9-13) had previously been found to have little or no antipyretic activity, but
a-MSH (8-13) was more potent than the a-MSH (11-13) molecule. Thus, adding
amino acids to the tripeptide antipyretic message sequence can both reduce and
enhance antipyretic activity. Although the bulk of the research has been upon the
a-MSH (1-13) molecule, it may be that COOH-terminal fragments of the peptide are
also important to modulation ofhost responses, with some, such as a-MSH (1 1-13) and
a-MSH (8-13), being more active.
INFLUENCE OF a-MSH ON THE ACUTE-PHASE RESPONSE
AND RELATED HOST RESPONSES
As described in detail elsewhere in this issue, cytokines can induce aspects of the
acute-phase response in addition to fever when administered centrally or peripherally.
The influence of their central administration is remarkable because it demonstrates a
link between CNS structures and peripheral responses that are normally attributed to
the immune system. Recent evidence indicates that actions of the cytokines can be
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antagonized by the neuropeptide a-MSH. For example, Robertson et al. [30] found
that a-MSH inhibited IL-1-induced fever, neutrophilia, and synthesis of serum
amyloid P (SAP) in a time- and dose-dependent fashion in mice; these changes were
not inhibited by ACTH or glucocorticoids. In related experiments from the same
laboratory [31], a-MSH inhibited fever, neutrophilia, SAP synthesis, and increases in
plasma corticosterone induced in mice by iv IL-I and also depressed contact hypersen-
sitivity; a stable analogue of a-MSH was more effective, but neither peptide altered
plasma PGE2 concentration. a-MSH given icv inhibited fever, leukocyte, and C-
reactive protein responses induced by central injection of endogenous pyrogen in
rabbits [43]. The neuropeptide likewiseinhibited fever and increases in SAPcaused by
recombinant IL-1 and TNF [32]. Injections of a-MSH into the fourth ventricle
inhibited neutrophilia, fever, SAP, and fibrinogenresponsescaused by therecombinant
molecules. Peripheral injection of a-MSH depressed contact hypersensitivity. These
results clearly indicate that a-MSH antagonism of cytokine effects is not limited to
fever but extends to multiple changes induced by the soluble mediators.
An increase in capillarypermeability is a hallmarkofinflammation, and it is possible
to reliably record this change in shorn rabbits given dye iv before intradermal
injections of histamine. At the site of histamine injection, the increase in capillary
permeability allows globulin with bound dye to leak through and color the skin. The
color intensity and diameter ofthe spots were less in rabbits given the tripeptide [23];
a-MSH (1-13) had a similar effect. In related experiments, increased capillary
permeability was induced by injecting endogenous pyrogen rather than histamine. In
these studies as well, a-MSH (1-13) inhibited the increase in capillary permeability
[24].
Recently, tests were performed using the mouse ear edema model, in which ear
swelling was induced by local application ofpicryl chloride [44]. a-MSH (11-13) given
intraperitoneally (ip) inhibited ear swelling in a dose-related fashion with reduced
effects at both low and high doses, a U-shaped relation characteristic of peptide
activity. The most effective dose of tripeptide was as effective as a large dose of the
corticosteroid prednisolone. Thesefindings thus confirm the anti-inflammatory activity
ofthe tripeptide in a different animal model.
Is it possible that a-MSH acts locally in the skin to inhibit inflammation? Does the
peptide migrate to sites of inflammation? The answers to these questions are not
complete. Early in our research on the peptide, a-MSH was injected into the skin in
doses up to 20 Atg along with histamine or endogenous pyrogen. There was no clear
inhibition by the peptide of increases in capillary permeability [Lipton JM: unpub-
lished observations]. Likewise, when the tripeptide or a-MSH (1-13) was injected
intradermally along with histamine, in two humans, the size ofwheals was not affected
[Lipton JM, Sullivan T: unpublished observations]. Although the studies were limited
and the possibility remains that effective doses were not discovered because of the
U-shaped nature ofpeptide activity, the data suggest that there is no local antagonism
between the peptide and histamine orcytokines at sites in the skin.
In separate experiments, endogenous pyrogen was injected intradermally in rabbits;
the skins were removed an hour later, aliquots containing the injection sites were
punched out of the frozen skin and, after processing, the concentration of a-MSH in
each site was determined. Endogenous pyrogen did not cause an influx ofpeptide: sites
injected with pyrogen had the same amount of a-MSH as saline-injected sites [Hiltz
ME, et al: unpublished observations]. These preliminary findings suggest that there is
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no natural migration of the anti-inflammatory peptide to high concentration of
cytokines in the skin.
Recent research on contact hypersensitivity induced in the mouse by picryl chloride
indicated that a-MSH (1-13) can inhibit the swelling associated with this response
[Hiltz ME, Lipton JM: unpublished observations]. Such hypersensitivity is cell-
mediated in man, presumably by T lymphocytes. The swelling in the mouse may,
however, be due to migration of cells, particularly polymorphonuclear leukocytes, and
the release of soluble agents (cytotoxins) from participating cells. The mechanism of
action of a-MSH may occur via an influence on granulocytes per se. Mason and Van
Epps [45] noted that neutrophil penetration into subdermal sponges injected with
cytokines was inhibited by intraperitoneal injections of a-MSH. It may be that a
similar action of a-MSH accounts for the influence on contact hypersensitivity. In
these recent studies, a-MSH inhibited neutrophil migration induced by IL-1, TNF,
and C5a. The effect on IL-I-induced granulocyte migration was dose-related; ACTH
had a lesser effect and,B-endorphin was ineffective. a-MSH had no effect on concentra-
tions of circulating neutrophils. The combined results suggest that a-MSH can act to
antagonize the actions of specific cytokines that are linked to inflammation and other
host defense reactions.
Our findings on anti-inflammatory activity of a-MSH molecules are consistent with
previous studies on urate crystal inflammation [46]. When a-MSH was injected along
with urate crystals into the hind paw of the rat, a small but consistent inhibition of
swelling was noted. In these experiments fl-endorphin and somatostatin were also
effective inhibitors, whereas neurotensin and substance P increased swelling.
There is little in vitro evidence on the effects of a-MSH in host cell responses.
Augmentation ofmurine thymocyte proliferation by IL-I and IL-I-stimulated produc-
tion of prostaglandin in fibroblasts was inhibited by a-MSH with a biphasic dose-
response relationship [47]. These results, and lack of influence on basal thymocyte
proliferation on IL-2-induced proliferation of a cytotoxic T-cell lymphocyte line, led to
the conclusion that a-MSH is an endogenous antagonist of IL-1, one that is relatively
specific. Others [3] did not observe inhibition by a-MSH of IL-1-induced thymocyte
proliferation or proliferation of an IL-I-responsive T-cell line. Although these in vitro
results are inconsistent, the marked effects of a-MSH in live animals are clear, and
they appear to reflect antagonism by the peptide ofseveral activities of IL-1.
EFFECTS OF HOST CHALLENGE UPON CIRCULATING a-MSH
The increased concentration ofa-MSH within the septal region after challenge with
endogenous pyrogen in both tissue-sampling and push-pull studies raised questions
about circulating levels ofa-MSH. This peptide has a short half-life in the circulation,
generally a few minutes, and there was no reason to believe that increases in the septal
region are necessarily associated with changes in concentration ofcirculating peptide.
Rabbits were given endogenous pyrogen icv or iv, and blood samples taken 0, 2, and 4
hours later were processed and assayed for a-MSH [3]. Central injections that caused
fever had no significant effect on a-MSH concentration, but iv pyrogen caused a
marked increase in the circulating peptide, presumably due to stimulation of both
peripheral and central pyrogen receptors. These results are very important to under-
standing the role of the neuropeptide in host defense, for they indicate that a-MSH
becomes available throughout the body in response to challenge, to modulate host
responses. It may be that the peptide and its fragments can penetrate the brain to
178a-MSH MODULATION
influence fever and other host responses and that circulating a-MSH inhibitsmigration
of cells in the periphery.
OTHER ACTIVITIES OF a-MSH (11-13)
This fragment of a-MSH has not been studied extensively, perhaps in part because
ofthe cost ofproducing custom peptides. Ingeneral, rather largedoses have been given
in a limited number of studies and the effects have been small. The fragment does not
appear to be involved in pigmentation since it exerts only weak activity in Rana and
Anolis melanophore assays [48,49]. It is perhaps not important to attention, learning,
and memory effects, unlike N-terminal a-MSH fragments, because it has only about
2.5 percent of the activity ofa-MSH (1-13) in delaying extinction in the pole-jumping
test [50]. It stimulates inner zone and capsular cells ofthe adrenal cortex ofthe rat, but
only in very large doses (10-5to 10-3 M); therefore this action may not be specific [51].
The molecule has been implicated in stimulation ofglycolysis, but not steroidogenesis,
in mouse adrenal cortical cells, although a-MSH (11-13) was not tested alone [52].
The activity ofdopamine neurons in the arcuate nucleus and the substantia nigra ofthe
rat, estimated from cellular fluorescence intensity, is altered by substantial doses of
a-MSH (11-13) [53]. The latter finding may be important to understanding the
mechanisms ofcentral actionofthe tripeptide, although a clear link betweendopamine
neurons and host responses has not been established. In summary, such research on the
a-MSH (11-13) molecule has been limited and mostly negative. The strongest
evidence of dose-related effects of a-MSH (11-13) is the research on antipyretic and
anti-inflammatory activities described above.
THE MECHANISMS OF ACTION OF a-MSH PEPTIDES
IN HOST DEFENSE
The current working hypothesis is that a-MSH, or its fragments, is released by, or
concomitantly with, cytokines. Evidence indicates that a-MSH concentrations within
the septum and in the circulation increase in the presence of cytokines. Circulating
a-MSH is then available throughout the body to modulate host responses. It may be
that circulating a-MSH likewise penetrates into the brain, but, because of barrier
systems, it appears more likely that smaller active fragments like a-MSH (11-13)
penetrate. How do a-MSH and COOH-terminal fragments antagonize the effects of
cytokines? There is as yet no clear answer. It is unlikely that a-MSH acts as an IL-I
receptor antagonist, since it does not appear todisplace thecytokine from CNS [54] or
lung tissue [Schmidt T; personalcommunication] receptors. a-MSH appears not to act
as a prostaglandin synthesis inhibitor like certain other antipyretics because it did not
antagonize hyperthermia induced by sodium arachidonate [55]. In whole-animal
models of inflammation, it may inhibit inflammation by preventing migration of
neutrophils into sites of high concentration ofcytokines [45], although this possibility
is unlikely to account for its central antipyretic properties. There is also evidence that
neutrophils increase vascular permeability [56]. Thus, an inhibition ofleukocytes may
be responsible for the inhibitory effects of a-MSH (1-13) and a-MSH (11-13) on
histamine- and endogenous pyrogen-induced increases in capillary permeability we
have observed, although this hypothesis remains to be determined. Thus, with this
bioactive peptide,just as with antipyretic and anti-inflammatory drugs that have been
studied for much longer, the picuture is incomplete. Discovery of the cellular and
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molecular activities ofa-MSH peptides in exerting antipyretic and anti-inflammatory
effects is a major aim offuture research.
POTENTIAL FOR THERAPEUTIC USE
a-MSH and its fragments are widespread in the body, and it may be that such
molecules are part ofa modulatory system that limits host responses. Ifthis hypothesis
is true, then it may be possible to use the a-MSH molecule, or, preferably, the shorter
a-MSH (11-13) message sequence, to control responses such as fever, neutrophilia,
and inflammation in injury and disease. Although much remains to be learned, it is
likely that treatment with a naturally occurring substance would be safer than
treatment with exogenous drugs. Indeed, treatment with large doses of a-MSH,
relative to antipyretic doses, arerequired centrally tocausetoxiceffects in rabbits [56].
Doses greater than 1 mg caused agitation, ataxia, and, in 30 percent of the animals,
death, but lesser amounts were not harmful. Thus, although the peptide is toxic when
given in large doses, the roughly 5,000-fold difference between antipyretic and lethal
doses provides a wide safety margin. In contrast, as little as 10 grams ofaspirin taken
orally has caused death in man [37], an amount only 15 times the common antipyretic
dose (650 mg).
If a-MSH peptides are to be used therapeutically, it is important that there be no
development of tolerance. When the antipyretic effect of central a-MSH against
endogenous pyrogen fever was tested, the a-MSH injected alone twice daily for ten
days, and the effect on fever was tested again, there was no sign oftolerance [58].
The duration ofaction ofa-MSH and the related peptides is relatively brief, perhaps
one to 1.5 hours in most cases. This briefaction allows more precise control, and there
is no concern about the agent remaining in the body for long periods. New molecular
configurations may provide a longer duration of action. Several molecular analogues
have already been developed, and one, Nle4-D-Phe7 (a-MSH), is even more potent in
reducing fever than a-MSH (1-13) when given centrally [59]. Unfortunately, the
molecule is not effective against fever when given peripherally. Because of its relative
safety, it may bepossible togivethe natural peptideinlargedoses and thus increasethe
duration ofeffect ofa single dose. In brief, the activity ofa-MSH molecules and their
prima facie safety suggests that such agents might be useful in treatment of clinical
disease, injury, and inflammation.
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